特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我 们的推送。 摘要 ： 脑机接口（BCI）领域需要整合神经科学、生物医学工程、材料科学等多领域的科学仪器，本 文带你解锁脑机接口背后的科学仪器清单。 2 0 2 5年1 2月3 1日，马斯克通过社交媒体宣布，其脑机接口公司Ne u r a li n k将于 2 0 2 6 年 启 动 脑 机接口设备的"大规模生产" ， 同时 计划将植入物的电极通道 数 量 提 升 至 3 0 0 0 个 ， 并 帮 助 首 位"盲视"项目参与者恢复低分辨率视觉。 马斯克的言论直接点燃了资本市场的热情。2 0 2 6年A股开年首个交易日，脑机接口相关概念股 出现涨停潮，显示出市场对该技术商业化的强烈预期。 同样，在中国市场，2 0 2 6年1月7日， 脑机接口企业强脑科技宣布完成约2 0亿元新一轮融资， 创下该领域除Neur a link外的全球第二大单笔融资纪录。 资本重金押注，足以印证脑机接口 （ BCI ） 赛道的巨大潜力，要实现从实验室到产业化的跨 越，科学仪器作为核心技术载体的作用至关重要。 脑机接口 （ BCI ...

Core Viewpoint - Fosun Pharma is set to acquire a controlling stake in Green Valley Pharmaceutical for approximately 1.412 billion yuan, aiming to advance the development of the Alzheimer's drug, Ganluo Sodium Capsule, which has faced regulatory challenges and halted production [1][3][6]. Group 1: Acquisition Details - Fosun Pharma's subsidiary plans to invest 1.43 billion yuan to acquire existing shares and 12.69 billion yuan for new capital, resulting in a 53% ownership stake in Green Valley [3][8]. - The acquisition is structured to address existing employee stock incentive plans and involves a transfer of shares at minimal cost to facilitate the deal [3][8]. Group 2: Product Background - Ganluo Sodium Capsule, approved in 2019 for treating mild to moderate Alzheimer's disease, has been recognized for its potential to improve cognitive function but has faced setbacks in commercial production due to regulatory issues [4][6]. - The drug's commercial production has ceased, and Green Valley reported a net loss of 6.761 million yuan in the first three quarters of the year, with total liabilities reaching 795 million yuan [7][8]. Group 3: Market Potential and Strategy - The Alzheimer's treatment market presents significant growth opportunities, with global sales projected at approximately 2.094 billion USD in 2024, while the Chinese market is expected to reach 1.244 billion yuan [10]. - Fosun Pharma aims to leverage this acquisition to enhance its product pipeline in the central nervous system treatment sector, addressing unmet clinical needs and expanding its market presence [11][13]. Group 4: Clinical Development Focus - The success of the acquisition hinges on the completion of confirmatory clinical trials for Ganluo Sodium Capsule, which are essential for regulatory approval and market re-entry [9][12]. - Fosun Pharma plans to conduct international multi-center studies to bolster the drug's academic credibility and support future market access [9][12].

Core Viewpoint - Fosun International (00656.HK) announced an agreement to acquire a stake in Green Valley (Shanghai) Pharmaceutical Technology, enhancing its position in the Alzheimer's disease treatment market [1][2]. Group 1: Acquisition Details - Fosun Pharma's subsidiary will acquire a total of 8.6667% equity in Green Valley, with a purchase price of RMB 143 million, and will subscribe to an additional capital increase of RMB 1,269,481,633, resulting in a total ownership of 46.3504% post-transaction [1]. - The transaction involves a special purpose vehicle (SPV) where Fosun Pharma and the founders will hold 51% and 49% stakes, respectively, facilitating the handling of employee stock buybacks [2]. Group 2: Market Context - Alzheimer's disease (AD) is a significant public health challenge with limited treatment options, and the market for AD treatments in China is underdeveloped, presenting substantial growth opportunities [3]. - The global sales for AD treatments are projected to reach approximately USD 2.094 billion in 2024, while the sales in China are expected to be only RMB 1.244 billion [3]. Group 3: Product Pipeline - The target company's Mannoheptulose capsules are indicated for mild to moderate Alzheimer's disease, showing significant cognitive improvement in clinical trials [4]. - Fosun Pharma is committed to advancing its product pipeline in the central nervous system disease sector, including ongoing clinical trials and the introduction of innovative treatment technologies [4].

Core Viewpoint - Fosun International announced an agreement to acquire a stake in Green Valley (Shanghai) Pharmaceutical Technology, enhancing its position in the Alzheimer's disease treatment market [1][2][3] Group 1: Acquisition Details - Fosun Pharma will acquire a total of 8.6667% of Green Valley's shares, with a purchase price of RMB 143 million, and will subscribe to additional registered capital amounting to RMB 1.269 billion, resulting in a total ownership of 46.3504% post-transaction [1][2] - The transaction involves a special purpose vehicle (SPV) where Fosun Pharma and the founders of Green Valley will hold 51% and 49% stakes, respectively, to manage employee buyback arrangements [2] Group 2: Market Context - Alzheimer's disease (AD) is a significant public health challenge with limited treatment options, and the market for AD treatments in China shows substantial growth potential, with a current sales figure of RMB 1.244 billion for 2024 [3][4] - The market for AD treatments globally is projected to reach USD 2.094 billion in 2024, indicating a strong demand for effective therapies [3] Group 3: Product Pipeline - Green Valley's Mannoheptulose capsules are aimed at treating mild to moderate Alzheimer's disease, showing significant cognitive improvement in clinical trials [4] - Fosun Pharma is expanding its product pipeline in the central nervous system disease sector, including non-invasive diagnostic and therapeutic solutions, and plans to conduct further clinical trials for the newly acquired drug [4]

Core Viewpoint - Fosun Pharma is investing 1.412 billion yuan to acquire a controlling stake in Green Valley Pharmaceutical, which focuses on the research, production, and sales of drugs for neurodegenerative diseases, particularly Alzheimer's disease [1][2]. Group 1: Investment Details - The acquisition will make Green Valley Pharmaceutical a subsidiary of Fosun Pharma [1]. - Green Valley's main product, Ganluo Sodium Capsule, received conditional approval from the National Medical Products Administration in November 2019 for treating mild to moderate Alzheimer's disease [1]. - The product is included in the national medical insurance directory as of 2021 [1]. Group 2: Financial Performance - In 2024, Green Valley is projected to achieve revenue of 572 million yuan and a pre-tax profit of 70.77 million yuan [2]. - From January to September 2025, Green Valley is expected to generate revenue of 102 million yuan but will incur a pre-tax loss of 67.61 million yuan due to the expiration of the original registration certificate [2]. Group 3: Strategic Focus - The investment is part of Fosun Pharma's strategy to enhance its presence in the central nervous system treatment sector, addressing unmet clinical needs in neurodegenerative diseases [3]. - The company plans to support the post-marketing confirmatory clinical trials for Ganluo Sodium Capsule to expedite its approval process [3]. - Fosun Pharma is also exploring a multi-technology approach to treatment solutions, including non-invasive diagnostic equipment and new oral drugs for Alzheimer's disease [3].

Core Insights - Quantum measurement technology with ultra-high sensitivity to weak magnetic fields is playing a role in medical diagnostics, particularly in detecting early signs of diseases through subtle magnetic field changes in the human body [1][2] - The application of "quantum + medical" technology has attracted investor attention, with discussions on the integration of quantum precision measurement and medical diagnostics at the recent 2025 Quantum Technology and Industry Conference [1] Industry Overview - The domestic market for biological magnetic technology devices has begun to see clinical validation in major hospitals for diagnosing cardiovascular diseases such as myocardial ischemia and heart failure, although pricing details have not yet been disclosed [2] - The potential market for cardiovascular diseases in China is estimated to be in the hundreds of billions, with 330 million patients, including over 10 million with coronary heart disease [2] - The medical device market in China has grown from over 200 billion yuan in 2018 to nearly 400 billion yuan in 2023, with projections to exceed 600 billion yuan by 2030, indicating a significant opportunity for quantum biological magnetic technology [2] Technological Development - The development of superconducting biological magnetic technology, including devices like magnetocardiograms and magnetoencephalograms, has been in progress for 20 years and is nearing commercialization [1] - Despite the promising applications, the high cost and complexity of biological magnetic technology currently limit its use as a routine clinical examination method [3] - Future advancements in high-temperature superconducting technology and the reduction in costs of quantum sensors are expected to make magnetocardiogram devices more affordable and widely applicable in clinical settings [3]

Core Insights - Shandong University has announced procurement intentions for 20 items of scientific instruments and equipment, with a total budget of 101 million yuan, expected to be procured between April and August 2025 [1][2]. Group 1: Procurement Overview - The procurement includes advanced instruments such as a triple quadrupole liquid chromatography mass spectrometer, magnetoencephalography (MEG) system, seismic micro-motion instrument, and a drag-type transient electromagnetic instrument [2][3]. - The budget allocation for specific items includes 2.3 million yuan for the mass spectrometer, 1.3 million yuan for the MEG system, 1.28 million yuan for the seismic instrument, and 1.35 million yuan for the electromagnetic instrument [3][5]. Group 2: Specific Equipment Details - The triple quadrupole liquid chromatography mass spectrometer is required to have a dual ion source configuration, high sensitivity, and a wide dynamic range [3]. - The MEG system is intended for non-invasive brain imaging research, capable of detecting magnetic signals from the brain for diagnostic purposes [3]. - The seismic micro-motion instrument will collect underground orthogonal tri-axial acceleration signals and features software tri-axial calibration without the need for precise leveling [3][5]. Group 3: Additional Equipment and Applications - Other notable procurements include a high-temperature environmental rock-groundwater disaster simulation system, a variable temperature Hall effect measurement system, and a dual-wavelength oscillator [5][6]. - The high-temperature simulation system aims to support research on geological disaster mechanisms under extreme conditions [5]. - The procurement also includes a zero-jitter multi-pulse laser light source and a multifunctional rapid drilling machine, which are designed for high-precision applications in various scientific fields [5][6].